Business & marketing tactics can boost recruitment

By Nick Taylor

- Last updated on GMT

Applying a business model based on marketing theory to clinical trials can give a consistent framework for planning and managing patient recruitment, say academics.

The need to overcome slow patient recruitment is driving the development of novel strategies, one of which is the adoption of business and marketing strategies. Although superficially very different, some believe business and clinical trials share many similarities.

“Businesses strive to find customers and encourage them to buy what is on offer, clinical trials strive to find doctors and patients/volunteers and encourage them to sign up and stay on board”, says the review published in the journal Trials.

The review looks at three studies, CRASH-2, TXT2STOP and LIFELAX, which used the business model to develop clinical trial processes, for diagnostics and as an audit tool respectively.

In the TXT2STOP trial, a study of smoking cessation support via text message, application of the business model “resulted in a new conceptualisation of recruitment”. This recognised the trial was being promoted to three distinct groups: directly to smokers; primary care teams; and smoking cessation services.

Recognising these groups led to the trial team identifying factors which would encourage them to participate and, conversely, elements likely to put them off. After adopting a strategy based around this knowledge the trial recruited 4,744 participants in 10 months; prior to the shift 1,056 had been recruited in eight and a half months.

Model parallels

The business model was proposed in a 2007 Trials paper. In the paper clinical trials were broken down into four units: building brand values; product and market planning; making the sale; and maintaining engagement.

Each unit, which includes three sub-units, uses business terminology but can be applied to the process of recruiting patients to a clinical trial. For instance, the building brand values component conveys what the trial 'stands for' to potential participants and collaborators.

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers